Loss of microbicidal activity and increased formation of biofilm due to decreased lactoferrin activity in patients with cystic fibrosis.
about
Antimicrobial proteins and polypeptides in pulmonary innate defenceThe transition metal gallium disrupts Pseudomonas aeruginosa iron metabolism and has antimicrobial and antibiofilm activityThe Role of Serine Proteases and Antiproteases in the Cystic Fibrosis LungNETs and CF Lung Disease: Current Status and Future ProspectsCandida albicans Inhibits Pseudomonas aeruginosa Virulence through Suppression of Pyochelin and Pyoverdine BiosynthesisActivity and interactions of liposomal antibiotics in presence of polyanions and sputum of patients with cystic fibrosisHuman cysteine cathepsins are not reliable markers of infection by Pseudomonas aeruginosa in cystic fibrosis.miR-31 dysregulation in cystic fibrosis airways contributes to increased pulmonary cathepsin S production.Combination of hypothiocyanite and lactoferrin (ALX-109) enhances the ability of tobramycin and aztreonam to eliminate Pseudomonas aeruginosa biofilms growing on cystic fibrosis airway epithelial cells.Role of elastases in the pathogenesis of chronic obstructive pulmonary disease: implications for treatmentEffects of airway surface liquid pH on host defense in cystic fibrosisPeak oxygen uptake and mortality in children with cystic fibrosis.Defective innate immunity and hyperinflammation in newborn cystic fibrosis transmembrane conductance regulator-knockout ferret lungsLactoferrin Is an Allosteric Enhancer of the Proteolytic Activity of Cathepsin G.Elastolytic proteases: inflammation resolution and dysregulation in chronic infective lung disease.Decreased levels of secretory leucoprotease inhibitor in the Pseudomonas-infected cystic fibrosis lung are due to neutrophil elastase degradation.CFTR, mucins, and mucus obstruction in cystic fibrosis.The DeltaF508-CFTR mutation results in increased biofilm formation by Pseudomonas aeruginosa by increasing iron availability.Elafin, an elastase-specific inhibitor, is cleaved by its cognate enzyme neutrophil elastase in sputum from individuals with cystic fibrosisProteases and cystic fibrosis.A Survival Strategy for Pseudomonas aeruginosa That Uses Exopolysaccharides To Sequester and Store Iron To Stimulate Psl-Dependent Biofilm Formation.Proteases and antiproteases in chronic neutrophilic lung disease - relevance to drug discovery.Inescapable need for neutrophils as mediators of cellular innate immunity to acute Pseudomonas aeruginosa pneumonia.The cystic fibrosis neutrophil: a specialized yet potentially defective cell.The role of proteases, endoplasmic reticulum stress and SERPINA1 heterozygosity in lung disease and α-1 anti-trypsin deficiency.The efficacy and safety of inhaled human α-1 antitrypsin in people with α-1 antitrypsin deficiency-related emphysema.Interactions between Pseudomonas aeruginosa and Staphylococcus aureus during co-cultivations and polymicrobial infections.Are There Any Other Compounds Isolated From Dermacoccus spp at All?Lactoferrin: Balancing Ups and Downs of Inflammation Due to Microbial Infections.Understanding the Entanglement: Neutrophil Extracellular Traps (NETs) in Cystic FibrosisImmunomodulatory Cell Therapy to Target Cystic Fibrosis Inflammation.Bovine lactoferrin inhibits the efficiency of invasion of respiratory A549 cells of different iron-regulated morphological forms of Pseudomonas aeruginosa and Burkholderia cenocepacia.Lactoferrin: A Natural Glycoprotein Involved in Iron and Inflammatory Homeostasis.The role of natural antimicrobial peptides during infection and chronic inflammation.Antiproteases as therapeutics to target inflammation in cystic fibrosis.Expression and antimicrobial function of bactericidal permeability-increasing protein in cystic fibrosis patientsAbnormalities in the pulmonary innate immune system in cystic fibrosisInhibitory effects of lactoferrin on growth and biofilm formation of Porphyromonas gingivalis and Prevotella intermedia.Phenazine-1-carboxylic acid promotes bacterial biofilm development via ferrous iron acquisition.Modified wound dressing with phyto-nanostructured coating to prevent staphylococcal and pseudomonal biofilm development.
P2860
Q24541575-B680F7A9-994C-45D0-9687-CE2DB29C3DCCQ24683150-E8072DFD-B66B-4C94-8BDB-D17ED2F42F9AQ26799771-4C1545E4-5E76-42C8-84EE-FA7F446BECCDQ26864316-9E1AB5D8-B33F-4D18-B407-C14DF6BFCB93Q27317563-DAEBDAD0-78CD-4CE9-85E4-AB1E2C53AE46Q28475562-1D41A029-90FF-41DE-9258-62E344DA8DB6Q34043367-8E7AC788-1190-4C99-A64E-58C8A544DD5CQ34480433-E1DE5ED6-D0B7-4374-8DA1-0E428442F999Q34710667-8FD1B5DE-1340-419D-846D-C5B0676A5106Q35179153-B0632C34-A5A3-4819-94A7-443539DF79FFQ35498296-DCF63747-59E9-46F1-86F5-D95D3A455EE4Q35537060-8F29AAFA-9520-4287-BF48-1E0F7386C696Q35816416-C501A730-4AEA-4615-81E3-1466C2D05D2EQ35961015-CDC47F54-E29F-430F-887A-B1D9137A192AQ36032652-FAB547C9-C28F-421F-9049-2342AEBC28A7Q36114167-FD8FEF27-6398-4974-B132-5969AB01AC95Q36186528-A08715FD-68E3-4998-9C2A-18C6160B5B8AQ36808070-3F3D7D2D-9D66-45CC-9E36-290B918869EBQ36973716-5FD0B5A6-2076-4623-AB54-B34AD05849CDQ37131650-07FD8BF1-4390-41BE-8B5D-EA55A1DD4549Q37343254-41B256EB-0886-44E6-9640-EBB008A9CC79Q37447482-A888F8A6-88F6-4852-AA2F-6A238560A5C0Q37451128-F74FAF64-AADA-4701-B6EA-C630A172914CQ37839809-B63C045A-0D7B-4B33-8F60-31276595252EQ37894093-F39B3E10-E1C3-4C60-B383-EA346DA27FB8Q38322575-6CE7CF5C-23FE-4820-8F20-678CE6530978Q38847303-E7BA9C3C-FFB8-4349-9C00-8266F5CED692Q38992115-D48D714A-62E9-406E-8E09-FC2B251A46A5Q39159902-888BD14F-4FC0-412A-8437-143EDC005A8DQ39253846-E2FDDEB4-951E-4DB2-B0E5-71882B1019DBQ39434813-C0F384B8-449B-43CF-904C-EDFDAE5A8EB8Q40003234-1B891BE8-0FB5-4406-8CE1-62E51C9D9562Q40043981-9521CC74-378D-4CE5-9495-DFE09DE9EA30Q40063866-4D8D7B81-1EFA-4888-A2E6-84DED4BDAC97Q40363808-C62BAE23-92F9-460D-AC9D-9D14ACED123DQ41903957-6482CBF8-5563-488F-B3D7-F91B983C356EQ42066758-3F3EBEB8-2095-4B33-A99B-D9278CC32850Q42086240-F46F19EA-D739-4DD5-9349-10666E011BB6Q42793534-C2C470D3-66CF-433D-BD46-698EC572DB70Q43152533-EEFB75B8-657E-4FD8-88F3-FDDA6DBA511C
P2860
Loss of microbicidal activity and increased formation of biofilm due to decreased lactoferrin activity in patients with cystic fibrosis.
description
2004 nî lūn-bûn
@nan
2004 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Loss of microbicidal activity ...... patients with cystic fibrosis.
@ast
Loss of microbicidal activity ...... patients with cystic fibrosis.
@en
Loss of microbicidal activity ...... patients with cystic fibrosis.
@nl
type
label
Loss of microbicidal activity ...... patients with cystic fibrosis.
@ast
Loss of microbicidal activity ...... patients with cystic fibrosis.
@en
Loss of microbicidal activity ...... patients with cystic fibrosis.
@nl
prefLabel
Loss of microbicidal activity ...... patients with cystic fibrosis.
@ast
Loss of microbicidal activity ...... patients with cystic fibrosis.
@en
Loss of microbicidal activity ...... patients with cystic fibrosis.
@nl
P2093
P921
P356
P1476
Loss of microbicidal activity ...... patients with cystic fibrosis
@en
P2093
Mark P Rogan
Noel G McElvaney
Philip G Murphy
Shane J O'Neill
P304
P356
10.1086/423821
P407
P577
2004-08-26T00:00:00Z